RxDoctor Payments Data

Moustafa Banna, MD

Cardiovascular Disease · Peoria, AZNPI 1003009861

Payments from drug & device makers

$24,685in general payments, 2019–2025

Across 492 payments — averaging $50.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$10K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Amgen$1K
  • Novartis$1K
  • Cardiva Medical, Inc.$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$987
  • plus $8K from 34 others

What the payments were for

  • Speaking & faculty fees$7,50030%
  • Food & beverage$17,06469%
  • Education$1210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,685 in reported general payments places this provider in the 85th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$270,524
Medicare patients
613
Services billed
2,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban366$472,292
ArcalystRilonacept11$253,153
EntrestoSacubitril/Valsartan103$121,567
XareltoRivaroxaban95$118,268
JardianceEmpagliflozin37$43,482
Repatha SureclickEvolocumab45$38,205
FarxigaDapagliflozin Propanediol33$28,769
VerquvoVericiguat18$19,789
BrilintaTicagrelor18$16,963
Metoprolol Succinate330$3,800
Flecainide Acetate77$3,721
Diltiazem 24hr Er (Cd)Diltiazem Hcl91$2,681
Ranolazine ErRanolazine37$2,350
Amlodipine-ValsartanAmlodipine Besylate/Valsartan36$2,282
Carvedilol268$2,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$313$472,292366 claims
Kiniksa Pharmaceuticals International, PLCArcalyst$33$253,15311 claims
NovartisEntresto$1,292$121,567103 claims
Johnson & JohnsonXarelto$82$118,26895 claims
AstraZenecaFarxiga, Brilinta$547$45,73251 claims
Boehringer IngelheimJardiance$509$43,48237 claims
MerckVerquvo$436$19,78918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →